Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Head and Neck Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 142 articles:
HTML format



Single Articles


    July 2021
  1. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV(+) Patients.
    Clin Cancer Res. 2021;27:4129.
    PubMed    


    June 2021
  2. FERRAROTTO R, Amit M, Nagarajan P, Rubin ML, et al
    Pilot phase II trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2021 Jun 29. pii: 1078-0432.CCR-21-0585.
    PubMed     Abstract available


  3. BURGENER JM, Zou J, Zhao Z, Zheng Y, et al
    Tumor-Naive Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021 Jun 22. pii: 1078-0432.CCR-21-0110.
    PubMed     Abstract available


    May 2021
  4. LEE RH, Kang H, Yom SS, Smogorzewska A, et al
    Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-1259.
    PubMed     Abstract available


    April 2021
  5. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    PubMed     Abstract available


  6. CATENACCI DVT
    A PERFECT biomarker-focused study of neoadjuvant IO for esophagogastric cancer.
    Clin Cancer Res. 2021 Apr 6. pii: 1078-0432.CCR-21-0324.
    PubMed     Abstract available


    March 2021
  7. HUI EP, Ma BBY, Lam WKJ, Chan A, et al
    A randomized trial of adjuvant chemotherapy versus observation in patients with nasopharyngeal carcinoma with detectable post-radiotherapy pEBV DNA.
    Clin Cancer Res. 2021 Mar 10. pii: 1078-0432.CCR-20-3519.
    PubMed     Abstract available


    February 2021
  8. MUDIANTO T, Campbell KM, Webb J, Zolkind P, et al
    YAP1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas.
    Clin Cancer Res. 2021 Feb 5. pii: 1078-0432.CCR-19-4179.
    PubMed     Abstract available


    January 2021
  9. CHAHOUD J, Gleber-Netto FO, McCormick BZ, Rao P, et al
    Whole Exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2021 Jan 13. pii: 1078-0432.CCR-20-4004.
    PubMed     Abstract available


  10. UPPALURI R, Campbell KM, Egloff AM, Zolkind P, et al
    Correction: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
    Clin Cancer Res. 2021;27:357.
    PubMed    


    November 2020
  11. HOLT JR, Walter V, Yin X, Marron D, et al
    Integrative analysis of microRNAs identifies clinically relevant epithelial and stromal subtypes of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-0557.
    PubMed     Abstract available


    October 2020
  12. CHEN Y, Li Z, Sun Y, Zhou GQ, et al
    An immune-related gene prognostic index for head and neck squamous cell carcinoma.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2166.
    PubMed     Abstract available


  13. TONG T, Zhong Y, Kong J, Dong L, et al
    Editor's Note: Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma.
    Clin Cancer Res. 2020;26:5540.
    PubMed    


    September 2020
  14. DAI W, Chung DL, Chow LK, Yu VZ, et al
    Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-2854.
    PubMed     Abstract available


  15. WANG D, Muller S, Ruhul Amin ARM, Huang D, et al
    Editor's Note: The Pivotal Role of Integrin beta1 in Metastasis of Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2020;26:5052.
    PubMed    


    August 2020
  16. CHONG WQ, Lim CM, Sinha AK, Tan CS, et al
    Integration of antiangiogenic therapy with cisplatin and gemcitabine chemotherapy in patients with nasopharyngeal carcinoma.
    Clin Cancer Res. 2020 Aug 14. pii: 1078-0432.CCR-20-1727.
    PubMed     Abstract available


    July 2020
  17. HARRINGTON KJ, Kong A, Mach N, Chesney J, et al
    Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
    Clin Cancer Res. 2020 Jul 15. pii: 1078-0432.CCR-20-1170.
    PubMed     Abstract available


  18. UPPALURI R, Campbell KM, Egloff AM, Zolkind P, et al
    Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial.
    Clin Cancer Res. 2020 Jul 14. pii: 1078-0432.CCR-20-1695.
    PubMed     Abstract available


  19. WANG S, Lin Y, Xiong X, Wang L, et al
    Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: Results of a phase II clinical trial.
    Clin Cancer Res. 2020 Jul 9. pii: 1078-0432.CCR-20-0113.
    PubMed     Abstract available


  20. COGHILL AE, Pfeiffer RM, Proietti C, Hsu WL, et al
    Correction: Identification of a Novel, EBV-based Antibody Risk Stratification Signature for Early Detection of Nasopharyngeal Carcinoma in Taiwan.
    Clin Cancer Res. 2020;26:3496.
    PubMed    


    June 2020
  21. XU J, Bai Y, Xu N, Li E, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Clin Cancer Res. 2020 Jun 19. pii: 1078-0432.CCR-19-3561.
    PubMed     Abstract available


    May 2020
  22. MCDANIEL NK, Iida M, Nickel KP, Longhurst CA, et al
    AXL mediates cetuximab and radiation resistance through tyrosine 821 and the c-ABL kinase pathway in head and neck cancer.
    Clin Cancer Res. 2020 May 21. pii: 1078-0432.CCR-19-3142.
    PubMed     Abstract available


  23. WEISS J, Sheth S, Deal AM, Grilley Olson JE, et al
    Concurrent definitive immunoradiotherapy for patients with Stage III-IV Head and Neck Cancer and Cisplatin contraindication.
    Clin Cancer Res. 2020 May 5. pii: 1078-0432.CCR-20-0230.
    PubMed     Abstract available


    April 2020
  24. GHOSH C, Kumar S, Kushchayeva Y, Gaskins K, et al
    A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
    Clin Cancer Res. 2020;26:2022-2036.
    PubMed     Abstract available


  25. MIGNION L, Acciardo S, Gourgue F, Joudiou N, et al
    Metabolic Imaging Using Hyperpolarized Pyruvate-Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts.
    Clin Cancer Res. 2020;26:1932-1943.
    PubMed     Abstract available


  26. SCHODER HM, Demetrio De Souza Franca P, Nakajima R, Burnazi EM, et al
    Safety and feasibility of PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer.
    Clin Cancer Res. 2020 Apr 3. pii: 1078-0432.CCR-19-3484.
    PubMed     Abstract available


    March 2020
  27. YANG L, Shen C, Pettit CJ, Li T, et al
    Wee1 Kinase Inhibitor AZD1775 Effectively Sensitizes Esophageal Cancer to Radiotherapy.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-19-3373.
    PubMed     Abstract available


  28. FENG B, Shen Y, Pastor X, Bieg M, et al
    Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer.
    Clin Cancer Res. 2020 Mar 11. pii: 1078-0432.CCR-19-3997.
    PubMed     Abstract available


  29. HERNANDEZ AL, Young CD, Bian L, Weigel K, et al
    PARP inhibition enhances radiotherapy of SMAD4 deficient human head and neck squamous cell carcinomas in experimental models.
    Clin Cancer Res. 2020 Mar 5. pii: 1078-0432.CCR-19-0514.
    PubMed     Abstract available


  30. MITANI Y, Lin SH, Pytynia KB, Ferrarotto R, et al
    Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.
    Clin Cancer Res. 2020;26:1175-1184.
    PubMed     Abstract available


    February 2020
  31. FRIEDMAN J, Moore EC, Zolkind P, Robbins Y, et al
    Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
    Clin Cancer Res. 2020;26:679-689.
    PubMed     Abstract available


    January 2020
  32. MONTANUY H, Martinez-Barriocanal A, Casado JA, Rovirosa L, et al
    Gefitinib and afatinib show potential efficacy for Fanconi anemia-related head and neck cancer.
    Clin Cancer Res. 2020 Jan 31. pii: 1078-0432.CCR-19-1625.
    PubMed     Abstract available


  33. LU G, Fakurnejad S, Martin BA, van den Berg NS, et al
    Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers.
    Clin Cancer Res. 2020 Jan 24. pii: 1078-0432.CCR-19-3717.
    PubMed     Abstract available


  34. GANCI F, Pulito C, Valsoni S, Sacconi A, et al
    PI3K inhibitors curtail MYC-dependent mutant p53 gain-of-function in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-2485.
    PubMed     Abstract available


  35. LIU C, Sadat SH, Ebisumoto K, Sakai A, et al
    Cannabinoids promote progression of HPV positive head and neck squamous cell carcinoma via p38 MAPK activation.
    Clin Cancer Res. 2020 Jan 13. pii: 1078-0432.CCR-18-3301.
    PubMed     Abstract available


  36. WEI T, Choi S, Buehler D, Anderson RA, et al
    A PI3K/AKT Scaffolding Protein, IQ Motif-Containing GTPase Associating Protein 1 (IQGAP1), Promotes Head and Neck Carcinogenesis.
    Clin Cancer Res. 2020;26:301-311.
    PubMed     Abstract available


    December 2019
  37. GREENE S, Robbins Y, Mydlarz WK, Huynh AP, et al
    Inhibition of MDSC trafficking with SX-682, a CXCR1/2 inhibitor, enhances NK cell immunotherapy in head and neck cancer models.
    Clin Cancer Res. 2019 Dec 17. pii: 1078-0432.CCR-19-2625.
    PubMed     Abstract available


  38. DE LA IGLESIA JV, Slebos RJ, Martin-Gomez L, Wang X, et al
    Effects of tobacco smoking on the tumor immune microenvironment in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2019 Dec 17. pii: 1078-0432.CCR-19-1769.
    PubMed     Abstract available


  39. RODRIGUEZ CP, Wu Q, Voutsinas J, Fromm JR, et al
    A phase II trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer.
    Clin Cancer Res. 2019 Dec 3. pii: 1078-0432.CCR-19-2214.
    PubMed     Abstract available


    November 2019
  40. LANDA I, Pozdeyev N, Knauf JA, Haugen BR, et al
    Genetics of Human Thyroid Cancer Cell Lines-Response.
    Clin Cancer Res. 2019;25:6883-6884.
    PubMed    


  41. GARCIA C, Cormier F, Groussin L
    Genetics of Human Thyroid Cancer Cell Lines-Letter.
    Clin Cancer Res. 2019;25:6882.
    PubMed    


  42. GUTKIND JS, Day TA, Lippman SM, Szabo E, et al
    Targeting mTOR in Head and Neck Cancer-Response.
    Clin Cancer Res. 2019;25:6555.
    PubMed    


  43. MASTERSON L, Lechner M, Jones TM
    Targeting mTOR in Head and Neck Cancer-Letter.
    Clin Cancer Res. 2019;25:6554.
    PubMed    


  44. WILLIAMS TM
    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Response.
    Clin Cancer Res. 2019;25:6557.
    PubMed    


  45. GOTTGENS EL, Rabold K, Span PN
    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Letter.
    Clin Cancer Res. 2019;25:6556.
    PubMed    


    October 2019
  46. HE LJ, Xie C, Wang ZX, Li Y, et al
    Submucosal saline injection followed by endoscopic ultrasound versus endoscopic ultrasound only for distinguishing between T1a and T1b esophageal cancer.
    Clin Cancer Res. 2019 Oct 15. pii: 1078-0432.CCR-19-1722.
    PubMed     Abstract available


    September 2019
  47. ZHOU L, Mudianto T, Ma X, Riley R, et al
    Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers.
    Clin Cancer Res. 2019 Sep 27. pii: 1078-0432.CCR-19-1351.
    PubMed     Abstract available


  48. BROSE MS, Schlumbeger M, Jeffers M, Kappeler C, et al
    Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase 3 DECISION Trial.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-3439.
    PubMed     Abstract available


  49. QIN Y, Wu CW, Taylor W, Sawas T, et al
    Discovery, validation, and application of novel methylated DNA markers for detection of esophageal cancer in plasma.
    Clin Cancer Res. 2019 Sep 16. pii: 1078-0432.CCR-19-0740.
    PubMed     Abstract available


  50. VENTZ S, Trippa L, Schoenfeld JD
    Lessons Learned from De-escalation trials in favorable risk HPV-associated Squamous Cell Head and Neck Cancer - A Perspective on future trial designs.
    Clin Cancer Res. 2019 Sep 16. pii: 1078-0432.CCR-19-0945.
    PubMed     Abstract available


    August 2019
  51. LABAN S, Gangkofner DS, Holzinger D, Schroeder L, et al
    Antibody responses to cancer antigens identify patients with a poor prognosis among HPV-positive and HPV-negative head and neck squamous cell carcinoma patients.
    Clin Cancer Res. 2019 Aug 23. pii: 1078-0432.CCR-19-1490.
    PubMed     Abstract available


  52. DE ROEST RH, Mes S, Brink A, Poell JB, et al
    Molecular characterization of locally relapsed head and neck cancer after concomitant chemoradiotherapy.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-0628.
    PubMed     Abstract available


  53. MELL LK, Shen H, Nguyen-Tan PF, Rosenthal DI, et al
    Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.
    Clin Cancer Res. 2019 Aug 16. pii: 1078-0432.CCR-19-1832.
    PubMed     Abstract available


  54. OH SH, Kim WY, Kim JH, Younes MN, et al
    Editor's Note: Identification of Insulin-Like Growth Factor Binding Protein-3 as a Farnesyl Transferase Inhibitor SCH66336-Induced Negative Regulator of Angiogenesis in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2019;25:4861.
    PubMed    


    July 2019
  55. YAMAMURA K, Izumi D, Kandimalla R, Sonohara F, et al
    Intratumoral Fusobacterium nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma.
    Clin Cancer Res. 2019 Jul 29. pii: 1078-0432.CCR-19-0318.
    PubMed     Abstract available


  56. GREALLY M, Chou JF, Chatila WK, Margolis M, et al
    Clinical and molecular predictors of response to immune checkpoint inhibitors in patients with advanced esophagogastric cancer.
    Clin Cancer Res. 2019 Jul 23. pii: 1078-0432.CCR-18-3603.
    PubMed     Abstract available


  57. DUVVURI U, George J, Kim S, Alvarado D, et al
    Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2019 Jul 15. pii: 1078-0432.CCR-18-3453.
    PubMed     Abstract available


  58. XIAO R, An Y, Ye W, Derakhshan A, et al
    Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV(-) and HPV(+) Head and Neck Cancers To TNFalpha, TRAIL, and Radiation Therapy.
    Clin Cancer Res. 2019 Jul 2. pii: 1078-0432.CCR-18-3802.
    PubMed     Abstract available


    June 2019
  59. FERRIS RL, Licitra L, Fayette J, Even C, et al
    Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Clin Cancer Res. 2019 Jun 25. pii: 1078-0432.CCR-18-3944.
    PubMed     Abstract available


  60. KURZROCK R, Ball DW, Zahurak ML, Nelkin BD, et al
    The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
    Clin Cancer Res. 2019 Jun 11. pii: 1078-0432.CCR-18-1881.
    PubMed     Abstract available


  61. BROOKS JM, Menezes AN, Ibrahim M, Archer L, et al
    Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer.
    Clin Cancer Res. 2019 Jun 10. pii: 1078-0432.CCR-18-3314.
    PubMed     Abstract available


    May 2019
  62. MCMICHAEL EL, Benner B, Atwal LS, Courtney NB, et al
    A phase I/II trial of cetuximab in combination with interleukin-12 administered to patients with unresectable primary or recurrent head and neck squamous cell carcinoma.
    Clin Cancer Res. 2019 May 29. pii: 1078-0432.CCR-18-2108.
    PubMed     Abstract available


  63. ROBB R, Yang L, Shen C, Wolfe A, et al
    Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF(V600E) Mutant Thyroid Cancer Cells by Constraining DNA Double-strand Break Repair.
    Clin Cancer Res. 2019 May 16. pii: 1078-0432.CCR-18-3625.
    PubMed     Abstract available


    April 2019
  64. PENG H, Dong D, Fang M, Li L, et al
    Prognostic Value of Deep Learning PET/CT-based Radiomics: Potential Role for Future Individual Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2019 Apr 11. pii: 1078-0432.CCR-18-3065.
    PubMed     Abstract available


  65. WON E, Basunia A, Chatila WK, Hechtman JF, et al
    Efficacy of combined VEGFR1-3, PDGFalpha/beta, and FGFR1-3 blockade using nintedanib for esophagogastric cancer.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3789.
    PubMed     Abstract available


  66. SHOUSHTARI AN
    About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-19-0658.
    PubMed     Abstract available


    February 2019
  67. MIYAUCHI S, Kim SS, Pang J, Gold KA, et al
    Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics.
    Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-0871.
    PubMed     Abstract available


  68. LEE JW, Parameswaran J, Sandoval-Schaefer T, Eoh KJ, et al
    Combined Aurora kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2019 Feb 12. pii: 1078-0432.CCR-18-0440.
    PubMed     Abstract available


  69. LANDA I, Pozdeyev N, Korch C, Marlow LA, et al
    Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
    Clin Cancer Res. 2019 Feb 8. pii: 1078-0432.CCR-18-2953.
    PubMed     Abstract available


  70. SALEH A, Cheng H, Martin SE, Si H, et al
    Integrated genomic and functional microRNA analysis identifies miR-30-5p as a tumor suppressor and potential therapeutic nanomedicine in head and neck cancer.
    Clin Cancer Res. 2019 Feb 5. pii: 1078-0432.CCR-18-0716.
    PubMed     Abstract available


    January 2019
  71. DIGOMANN D, Kurth I, Tyutyunnykova A, Chen O, et al
    The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity.
    Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2951.
    PubMed     Abstract available


  72. XU J, Zhang Y, Jia R, Yue C, et al
    Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study.
    Clin Cancer Res. 2019;25:515-523.
    PubMed     Abstract available


  73. SANTEGOETS SJ, van Ham VJ, Ehsan I, Charoentong P, et al
    The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival.
    Clin Cancer Res. 2019;25:240-252.
    PubMed     Abstract available


  74. VOZENIN MC, De Fornel P, Petersson K, Favaudon V, et al
    The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients.
    Clin Cancer Res. 2019;25:35-42.
    PubMed     Abstract available


    December 2018
  75. HUANG L, David O, Cabay RJ, Valyi-Nagy K, et al
    Molecular Classification of Lymph Node Metastases Subtypes Predict for Survival in Head and Neck Cancer.
    Clin Cancer Res. 2018 Dec 20. pii: 1078-0432.CCR-18-1884.
    PubMed     Abstract available


  76. LI F, Xu Y, Liu B, Singh PK, et al
    YAP1-mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the combination of YAP1 and CDK4/6 inhibitors in Esophageal Cancer.
    Clin Cancer Res. 2018 Dec 18. pii: 1078-0432.CCR-18-1029.
    PubMed     Abstract available


  77. CALIFANO JA, Khan Z, Noonan KA, Rudraraju L, et al
    Correction: Tadalafil Augments Tumor-specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2018;24:6100.
    PubMed    


  78. BRAND TM, Iida M, Stein AP, Corrigan KL, et al
    Correction: AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2018;24:6099.
    PubMed    


    November 2018
  79. ZHANG H, Hua Y, Jiang Z, Yue J, et al
    Cancer associated fibroblasts-promoted LncRNA DNM3OS confers radioresistance by regulating DNA damage response in esophageal squamous cell carcinoma.
    Clin Cancer Res. 2018 Nov 21. pii: 1078-0432.CCR-18-0773.
    PubMed     Abstract available


  80. DAY TA, Shirai K, O'Brien PE, Matheus MG, et al
    Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.
    Clin Cancer Res. 2018 Nov 12. pii: 1078-0432.CCR-18-2024.
    PubMed     Abstract available


  81. CLUMP DA, Pickering CR, Skinner HD
    Predicting Outcome in Head and Neck Cancer: miRNAs with potentially big effects.
    Clin Cancer Res. 2018 Nov 9. pii: 1078-0432.CCR-18-3078.
    PubMed     Abstract available


    October 2018
  82. DILLON MT, Grove L, Newbold KL, Shaw H, et al
    Patritumab with Cetuximab Plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase-Ib Study.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-1539.
    PubMed     Abstract available


  83. MITMAKER EJ, Tabah R, How J
    Thyroid Nodule DNA Methylation Signatures: An Important Diagnostic Annotation.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-2820.
    PubMed     Abstract available


  84. SONG YS, Kim MJ, Sun HJ, Kim HH, et al
    Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth.
    Clin Cancer Res. 2018 Oct 12. pii: 1078-0432.CCR-18-0663.
    PubMed     Abstract available


    September 2018
  85. AGGARWAL C, Cohen RB, Morrow MP, Kraynak KA, et al
    Immunotherapy targeting HPV 16/18 generates potent immune responses in HPV-Associated Head and Neck Cancer.
    Clin Cancer Res. 2018 Sep 21. pii: 1078-0432.CCR-18-1763.
    PubMed     Abstract available


  86. LUO J, Bian L, Blevins MA, Wang D, et al
    Smad7 Promotes Healing of Radiotherapy-Induced Oral Mucositis without Compromising Oral Cancer Therapy in a Xenograft Mouse Model.
    Clin Cancer Res. 2018 Sep 5. pii: 1078-0432.CCR-18-1081.
    PubMed     Abstract available


    August 2018
  87. HESS J, Unger K, Maihoefer C, Schuttrumpf L, et al
    A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection.
    Clin Cancer Res. 2018 Aug 31. pii: 1078-0432.CCR-18-0776.
    PubMed     Abstract available


  88. LI YQ, Yang XJ, Du XJ, Lei Y, et al
    RAB37 hypermethylation regulates metastasis and resistance to docetaxel-based induction chemotherapy in nasopharyngeal carcinoma.
    Clin Cancer Res. 2018 Aug 21. pii: 1078-0432.CCR-18-0532.
    PubMed     Abstract available


  89. YIM JH, Choi AH, Li AX, Qin H, et al
    Identification of Tissue Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0841.
    PubMed     Abstract available


  90. LIU Q, Ma L, Jones T, Palomero L, et al
    Subjugation of TGFbeta Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End-Joining.
    Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-1346.
    PubMed     Abstract available


  91. PRETE A, Lo AS, Sadow PM, Bhasin SS, et al
    Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFbeta1 axis.
    Clin Cancer Res. 2018 Aug 3. pii: 1078-0432.CCR-18-0693.
    PubMed     Abstract available



  92. Correction: A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck.
    Clin Cancer Res. 2018;24:3781.
    PubMed    


    July 2018
  93. XU M, Casio M, Range DE, Sosa JA, et al
    Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-17-3705.
    PubMed     Abstract available


  94. KARAM SD, Reddy K, Blatchford P, Waxweiler T, et al
    Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
    Clin Cancer Res. 2018 Jul 3. pii: 1078-0432.CCR-18-0467.
    PubMed     Abstract available


    June 2018
  95. LIU C, Guo T, Xu G, Sakai A, et al
    Characterization of alternative splicing events in HPV negative head and neck squamous cell carcinoma identifies an oncogenic DOCK5 variant.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0752.
    PubMed     Abstract available


    May 2018
  96. BHATIA S, Sharma J, Bukkapatnam S, Oweida A, et al
    Inhibition of EphB4-ephrin-B2 signaling enhances response to Cetuximab-radiation therapy in head and neck cancers.
    Clin Cancer Res. 2018 May 30. pii: 1078-0432.CCR-18-0327.
    PubMed     Abstract available


  97. TAN YS, Sansanaphongpricha K, Xie Y, Donnelly CR, et al
    Mitigating SOX2-potentiated immune escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing nanosatellite vaccine.
    Clin Cancer Res. 2018 May 16. pii: 1078-0432.CCR-17-2807.
    PubMed     Abstract available


    April 2018
  98. LIU Z, McMichael EL, Shayan G, Li J, et al
    Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients.
    Clin Cancer Res. 2018 Apr 30. pii: 1078-0432.CCR-17-1350.
    PubMed     Abstract available


  99. THAKUR S, Daley B, Gaskins K, Vasko VV, et al
    Metformin targets Mitochondrial Glycerophosphate Dehydrogenase (mGPDH) to control Rate of Oxidative Phosphorylation and growth of thyroid cancer in vitro and in vivo.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-17-3167.
    PubMed     Abstract available


    March 2018
  100. XU C, Nikolova O, Basom R, Mitchell RM, et al
    Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer.
    Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-1339.
    PubMed     Abstract available


  101. MENDEZ E, Rodriguez CP, Kao M, Raju SC, et al
    A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-3796.
    PubMed     Abstract available


  102. ZHAO X, Brusadelli MG, Sauter SL, Butsch Kovacic M, et al
    Lipidomic profiling links the Fanconi anemia pathway to glycosphingolipid metabolism in head and neck cancer cells.
    Clin Cancer Res. 2018 Mar 12. pii: 1078-0432.CCR-17-3686.
    PubMed     Abstract available


    February 2018
  103. SOULIERES D, Lictira L, Mesia R, Remenar E, et al
    Molecular Alterations and Buparlisib Efficacy in Patients With Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis From BERIL-1.
    Clin Cancer Res. 2018 Feb 28. pii: 1078-0432.CCR-17-2644.
    PubMed     Abstract available


  104. CHEN YP, Tang LL, Yang Q, Poh SS, et al
    Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials.
    Clin Cancer Res. 2018 Feb 5. pii: 1078-0432.CCR-17-2656.
    PubMed     Abstract available


  105. LABAN S, Hoffmann TK
    Human Papillomavirus Immunity in Oropharyngeal Cancer: Time to Change the Game?
    Clin Cancer Res. 2018;24:505-507.
    PubMed     Abstract available


    January 2018
  106. HUI EP, Ma BBY, Loong H, Mo F, et al
    Efficacy, safety and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase 2 correlative study.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1667.
    PubMed     Abstract available


  107. COGHILL AE, Pfeiffer RM, Proietti C, Hsu WL, et al
    Identification of a novel, EBV-based antibody risk stratification signature for early detection of nasopharyngeal carcinoma in Taiwan.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-1929.
    PubMed     Abstract available


  108. HANNA GJ, Busaidy NL, Chau NG, Wirth LJ, et al
    Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2297.
    PubMed     Abstract available


  109. SCHMIDT S, Linge A, Zwanenburg A, Leger S, et al
    Development and validation of a gene signature for patients with head and neck squamous cell carcinomas treated by postoperative radio(chemo)therapy.
    Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-2345.
    PubMed     Abstract available


    December 2017
  110. THEODORAKI MN, Yerneni S, Hoffmann TK, Gooding WE, et al
    Clinical significance of PD-L1+ exosomes in plasma of Head and Neck Cancer patients.
    Clin Cancer Res. 2017 Dec 12. pii: 1078-0432.CCR-17-2664.
    PubMed     Abstract available


  111. CHUNG MK, Jung YH, Lee JK, Cho SY, et al
    CD271 Confers an Invasive and Metastatic Phenotype of Head and Neck Squamous Cell Carcinoma Through the Upregulation of Slug.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-0866.
    PubMed     Abstract available


    November 2017
  112. KRAFT IL, Akshintala S, Zhu YJ, Lei H, et al
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res. 2017 Nov 29. pii: 1078-0432.CCR-17-2101.
    PubMed     Abstract available


  113. WANG X, Beitler JJ, Huang W, Chen G, et al
    Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-0345.
    PubMed     Abstract available


  114. FUKUSUMI T, Guo T, Sakai A, Ando M, et al
    The NOTCH4-HEY1 pathway induces epithelial mesenchymal transition in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2017 Nov 16. pii: clincanres.1366.2017.
    PubMed     Abstract available


  115. ZHONG Q, Liu Z, Lin ZR, Hu ZD, et al
    The RARS-MAD1L1 Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Nov 13. pii: clincanres.0352.2016.
    PubMed     Abstract available


  116. LIU X, Kumar M, Yang L, Molkentine DP, et al
    BAP1 is a novel target in HPV negative head and neck cancer.
    Clin Cancer Res. 2017 Nov 7. pii: clincanres.1573.2017.
    PubMed     Abstract available


  117. LIN C, Zhang N, Wang Y, Wang Y, et al
    Functional Role of A Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis.
    Clin Cancer Res. 2017 Nov 3. pii: clincanres.1851.2017.
    PubMed     Abstract available


    October 2017
  118. SHAYAN G, Kansy BA, Gibson SP, Srivastava RM, et al
    A Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.0357.2017.
    PubMed     Abstract available


  119. NIEHR F, Eder T, Pilz T, Konschak R, et al
    Multilayered omics-based analysis of a head and neck cancer model of cisplatin resistance reveals intratumoral heterogeneity and treatment-induced clonal selection.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.2410.2017.
    PubMed     Abstract available


  120. YANG Q, Zhang MX, Zou X, Liu YP, et al
    A prognostic bio-model based on SQSTM1 and N stage identifies nasopharyngeal carcinoma patients at high risk of metastasis for additional induction chemotherapy.
    Clin Cancer Res. 2017 Oct 13. pii: clincanres.1963.2017.
    PubMed     Abstract available


  121. MIN IM, Shevlin E, Vedvyas Y, Zaman M, et al
    CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors.
    Clin Cancer Res. 2017 Oct 12. pii: clincanres.2008.2017.
    PubMed     Abstract available


    September 2017
  122. WOOD O, Clarke J, Woo J, Mirza AH, et al
    Head and neck squamous cell carcinomas are characterized by a stable immune signature within the primary tumor over time.
    Clin Cancer Res. 2017 Sep 26. pii: clincanres.0373.2017.
    PubMed     Abstract available


  123. BIKTASOVA AK, Hajek M, Sewell AB, Gary CS, et al
    Demethylation therapy as a targeted treatment for human papilloma virus-associated head and neck cancer.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1438.2017.
    PubMed     Abstract available


    July 2017
  124. WHITESIDE TL
    Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1261.2017.
    PubMed     Abstract available


  125. MELL LK, Brumund KT, Daniels GA, Advani SJ, et al
    PHASE I TRIAL OF INTRAVENOUS ONCOLYTIC VACCINIA VIRUS (GL-ONC1) WITH CISPLATIN AND RADIOTHERAPY IN PATIENTS WITH LOCOREGIONALLY ADVANCED HEAD AND NECK CARCINOMA.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3232.2016.
    PubMed     Abstract available


    June 2017
  126. IBRAHIMPASIC T, Xu B, Landa I, Dogan S, et al
    Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence.
    Clin Cancer Res. 2017 Jun 20. pii: clincanres.1183.2017.
    PubMed     Abstract available


  127. LU G, Little JV, Wang X, Zhang H, et al
    Detection of Head and Neck Cancer in Surgical Specimens Using Quantitative Hyperspectral Imaging.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0906.2017.
    PubMed     Abstract available


  128. KOTIAN S, Zhang L, Boufraqech M, Gaskins K, et al
    Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.1043.2017.
    PubMed     Abstract available


    May 2017
  129. OZAWA H, Ranaweera R, Izumchenko E, Makarev E, et al
    SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells.
    Clin Cancer Res. 2017 May 18. pii: clincanres.1686.2016.
    PubMed     Abstract available


  130. CHOW LQM, Morishima C, Eaton KD, Baik CS, et al
    Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
    Clin Cancer Res. 2017;23:2442-2450.
    PubMed     Abstract available


  131. SKINNER HD, Giri U, Yang LP, Kumar M, et al
    Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2017 May 5. doi: 10.1158/1078-0432.CCR-16-2586.
    PubMed     Abstract available


  132. TZENG HT, Tsai CH, Yen YT, Cheng HC, et al
    Dysregulation of Rab37-Mediated Cross-talk between Cancer Cells and Endothelial Cells via Thrombospondin-1 Promotes Tumor Neovasculature and Metastasis.
    Clin Cancer Res. 2017;23:2335-2345.
    PubMed     Abstract available


  133. UPPALURI R, Winkler AE, Lin T, Law JH, et al
    Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial.
    Clin Cancer Res. 2017;23:2186-2194.
    PubMed     Abstract available


    April 2017
  134. ROSENTHAL E, Moore L, Tipirneni K, de Boer E, et al
    Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2968.2016.
    PubMed     Abstract available


  135. SALOURA V, Fatima A, Zewde M, Kiyotani K, et al
    Characterization of the tumor T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2017 Apr 25. pii: clincanres.0103.2017.
    PubMed     Abstract available


  136. LUDWIG S, Floros T, Theodoraki MN, Hong CS, et al
    Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.2819.2016.
    PubMed     Abstract available


    March 2017
  137. DERAKHSHAN A, Chen Z, Van Waes C
    Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.
    Clin Cancer Res. 2017;23:1379-1387.
    PubMed     Abstract available


    January 2017
  138. KANG H, Tan M, Bishop JA, Jones S, et al
    Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.
    Clin Cancer Res. 2017;23:283-288.
    PubMed     Abstract available


    October 2016
  139. RAUE F, Frank-Raue K
    Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Clin Cancer Res. 2016;22:5012-5021.
    PubMed     Abstract available


    July 2016
  140. ZHU X, Enomoto K, Zhao L, Zhu YJ, et al
    Bromodomain and extraterminal protein inhibitor JQ1 suppresses thyroid tumor growth in a mouse model.
    Clin Cancer Res. 2016 Jul 20. pii: clincanres.0914.2016.
    PubMed     Abstract available


    June 2016
  141. ABDULGHANI J, Gokare P, Gallant JN, Dicker DT, et al
    Sorafenib and quinacrine target anti-apoptotic protein Mcl-1: a poor prognostic marker in anaplastic thyroid cancer (ATC).
    Clin Cancer Res. 2016 Jun 15. pii: clincanres.2792.2015.
    PubMed     Abstract available


    February 2016
  142. YU XM, Jaskula-Sztul R, Georgen MR, Aburjania Z, et al
    Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression.
    Clin Cancer Res. 2016 Feb 4. pii: clincanres.1749.2015.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: